ALB and triple-negative breast carcinoma: Hebao Yuan and colleagues pioneered groundbreaking research demonstrating that, compared with conventional taxane formulations, albumin nanoparticle formulations of paclitaxel (Abraxane) fundamentally alter cancer stem cell dynamics in triple-negative breast cancer.